Dr. Joseph Mikhael:
If you know myeloma, you've probably heard of bispecific antibodies, but have you heard of trispecific antibodies? Hi everyone. Dr. Joseph Mikhael here from the International Myeloma Foundation, and I'm going to explain the difference in a minute or less.
Bispecific antibodies are an amazing new therapy that we have for multiple myeloma that are called bispecifics because they have two arms. One arm hooks onto something on the surface of myeloma we call an antigen, and the other hooks onto a T-cell to activate that T-cell to destroy the multiple myeloma. They have really revolutionized the way we treat myeloma, but now we're introducing trispecifics that have three arms, two arms that typically hook onto the myeloma and a third arm that engages that T-cell. The rationale for this is amazing really because it's allowing us to be even more precise in hooking onto the multiple myeloma so that we don't have off-target effects, and allows us to use actually less of the drug so there are fewer side effects. Stay tuned for what is coming with new trispecific antibodies in multiple myeloma.
For more information about multiple myeloma or if you have questions, please come and visit us at myeloma.org.
